185 related articles for article (PubMed ID: 2360238)
1. Factor IX concentrate versus prothrombin complex concentrate for the treatment of hemophilia B during surgery.
Bardin JM; Sultan Y
Transfusion; 1990 Jun; 30(5):441-3. PubMed ID: 2360238
[TBL] [Abstract][Full Text] [Related]
2. Purified factor IX using monoclonal immunoaffinity technique: clinical trials in hemophilia B and comparison to prothrombin complex concentrates.
Kim HC; McMillan CW; White GC; Bergman GE; Horton MW; Saidi P
Blood; 1992 Feb; 79(3):568-75. PubMed ID: 1531035
[TBL] [Abstract][Full Text] [Related]
3. Combined factor IX and protein C deficiency in a child: thrombogenic effects of two factor IX concentrates.
Negrier C; Vial J; Vinciguerra C; Berruyer M; Dechavanne M
Am J Hematol; 1995 Feb; 48(2):120-4. PubMed ID: 7847325
[TBL] [Abstract][Full Text] [Related]
4. Clinical experience of a new monoclonal antibody purified factor IX: half-life, recovery, and safety in patients with hemophilia B.
Kim HC; McMillan CW; White GC; Bergman GE; Saidi P
Semin Hematol; 1990 Apr; 27(2 Suppl 2):30-5. PubMed ID: 2094957
[TBL] [Abstract][Full Text] [Related]
5. Products for the treatment of hemophilia A and B prepared by ion exchange chromatography.
Sultan Y; Boyeldieu D; Stieltjes N
Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S59-60. PubMed ID: 8177717
[TBL] [Abstract][Full Text] [Related]
6. Prothrombal: a new concentrate of human prothrombin complex for clinical use.
Bruning PF; Loeliger EA
Br J Haematol; 1971 Oct; 21(4):377-98. PubMed ID: 5001176
[No Abstract] [Full Text] [Related]
7. Preparation and clinical use of factor IX concentrate PPSB according to Soulier.
Haanen C; McShine RL; Kunst A
Vox Sang; 1969 Apr; 16(4):398-411. PubMed ID: 5800593
[No Abstract] [Full Text] [Related]
8. Myocardial infarction after FEIBA therapy in a hemophilia-B patient with a factor IX inhibitor.
Mizon P; Goudemand J; Jude B; Marey A
Ann Hematol; 1992 Jun; 64(6):309-11. PubMed ID: 1637888
[TBL] [Abstract][Full Text] [Related]
9. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
[TBL] [Abstract][Full Text] [Related]
10. Perioperative Management of Mild Hemophilia B During and After Coronary Artery Bypass Grafting: Challenges and Solutions.
Fernando RJ; Farmer BE; Augoustides JG; Gardner JC; Johnson SD; Ha B; Friess JO; Luedi MM; Erdoes G; Miller PJ; Ripat C; Fabbro M
J Cardiothorac Vasc Anesth; 2019 Feb; 33(2):549-555. PubMed ID: 30177475
[No Abstract] [Full Text] [Related]
11. Optimizing the treatment of haemophilia B: laboratory and clinical perspectives.
Aledort LM
Haemophilia; 2010 Jul; 16 Suppl 6():1-2. PubMed ID: 20561350
[TBL] [Abstract][Full Text] [Related]
12. A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrate.
Goudemand J; Peynet J; Chambost H; Négrier C; Briquel ME; Claeyssens S; Derlon-Borel A; Guérois C; Caron C; Scherrmann JM; Debray M; Bridey F
Thromb Haemost; 1998 Dec; 80(6):919-24. PubMed ID: 9869161
[TBL] [Abstract][Full Text] [Related]
13. Markers of hypercoagulability in patients with hemophilia B given repeated, large doses of factor IX concentrates during and after surgery.
Santagostino E; Mannucci PM; Gringeri A; Tagariello G; Baudo F; Bauer KA; Rosenberg RD
Thromb Haemost; 1994 Jun; 71(6):737-40. PubMed ID: 7974341
[TBL] [Abstract][Full Text] [Related]
14. An open clinical study assessing the efficacy and safety of Factor IX Grifols, a high-purity Factor IX concentrate, in patients with severe haemophilia B.
Lissitchkov T; Matysiak M; Zawilska K; Gercheva L; Antonov A; Montañes M; Paez A
Haemophilia; 2010 Mar; 16(2):240-6. PubMed ID: 20015218
[TBL] [Abstract][Full Text] [Related]
15. Reduced bleeding events with subcutaneous administration of recombinant human factor IX in immune-tolerant hemophilia B dogs.
Russell KE; Olsen EH; Raymer RA; Merricks EP; Bellinger DA; Read MS; Rup BJ; Keith JC; McCarthy KP; Schaub RG; Nichols TC
Blood; 2003 Dec; 102(13):4393-8. PubMed ID: 12933577
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate.
Ruiz-Sáez A; Hong A; Arguello A; Echenagucia M; Boadas A; Fabbrizzi F; Minichilli F; Bosch NB
Haemophilia; 2005 Nov; 11(6):583-8. PubMed ID: 16236107
[TBL] [Abstract][Full Text] [Related]
17. Adherence to clotting factors among persons with hemophilia A or B.
Armstrong EP; Malone DC; Krishnan S; Wessler MJ
Hematology; 2015 Apr; 20(3):148-53. PubMed ID: 25001343
[TBL] [Abstract][Full Text] [Related]
18. Heparin supplement counteracts the prohemostatic effect of prothrombin complex concentrate and factor IX concentrate: An in vitro evaluation.
Brinkman HJ; Patiwael S; Tripathi S; Meijers JC
Thromb Res; 2016 Mar; 139():102-10. PubMed ID: 26916304
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Safety and Efficacy of Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Previously Treated Pediatric Patients with Hemophilia B: Results from a Phase 3b Extension Study.
Kenet G; Chambost H; Male C; Halimeh S; Lambert T; Li Y; Seifert W; Santagostino E
Thromb Haemost; 2020 Apr; 120(4):599-606. PubMed ID: 32185782
[TBL] [Abstract][Full Text] [Related]
20. [Prophylaxis in haemophilia B. Prevention of bleeds and FIX consumption].
Siegmund B; Richter H; Pollmann H
Hamostaseologie; 2010 Nov; 30 Suppl 1():S35-8. PubMed ID: 21042666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
